|
|
|
Course Title |
|
Molybdenum Cofactor Deficiency (MoCD): Recognition, Challenges, and Treatment |
|
|
Faculty |
|
Judy Aschner, MD
Professor and Chair of Pediatrics
Albert Einstein College of Medicine
Bronx, NY, USA
Guenter Schwarz, PhD
Professor and Chair of Biochemistry
University of Cologne
Germany
Alex Veldman, MD
Assistant Professor
Monash University
Australia
|
|
|
Program Overview |
|
To date, MoCD has been reported in more than 100 patients worldwide, but actual numbers are likely to be higher due to lack of recognition or misdiagnosis. There is a need for better recognition of this rare disease by neonatologists. |
|
|
Target Audience |
|
The program’s target audience will consist of pediatric and neonatal physicians, hospital and practice administrators, nurses, and other clinicians who interact with parents of newborns. |
|
|
Learning Objectives |
|
After participating in this program, the medical professional should be able to:
• Describe MoCD as an autosomal recessive metabolic disorder and list the enzymes whose activities are lost
• State the consequences of loss of molybdenum cofactor dependent enzyme activities
• Recognize the presenting symptoms of MoCD, and be aware of the most common misdiagnoses
• Know the specific tests required to provide an accurate differential diagnosis of MoCD
• Recognize the time course of neurological sequelae in infants with MoCD
• Describe new treatment options for patients with MoCD
• Recognize the importance of early diagnosis and intervention in MoCD, including the possibility of prenatal diagnosis
|
|
|
Credit Designation Statement(s) |
|
Statement of Credit—Participants who successfully complete this activity (including scoring at least 70% on the post-test and completing and submitting the evaluation form with an e-mail address) will receive a statement of credit via e-mail.
Physicians
The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Meniscus Educational Institute designates this internet enduring activity (275.001-1317-MI) for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity (275.001-1313-NI) for 1.00 contact hour is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center’s Commission on Accreditation of any product mentioned.
Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.00 contact hour. |
|
|
Financial Disclosure Statement |
|
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
|
|
|
Faculty Disclosure |
|
Judy Aschner, MD, owns stock in Gilead Sciences, Inc.
Guenter Schwarz, PhD, has a leadership position at Colbourne Pharmaceuticals GmbH and has served as a consultant for Alexion Pharmaceuticals.
Alex Veldman, MD, has a leadership position at CSL Behring and has served as a consultant for Colbourne Pharmaceuticals GmbH and Alexion Pharmaceuticals. |
|
|
Planners and Managers Disclosure List |
|
Planners, Content Reviewers
Robert Bieber has nothing to disclose.
Terry Logan has nothing to disclose.
Alexandra Novitsky, MD, has nothing to disclose.
Molly Thompson has nothing to disclose.
|
|
|
Disclaimer |
|
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management. |
|
|
Product Disclosure |
|
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product. |
|
|
Fee Statement |
|
There is no fee for participating in this activity. |
|
|
Hardware and Software Requirements
|
|
This program requires the use of Adobe Flash Player and is compatible with Internet Explorer 6 and up, Firefox, and Safari. |
|
|
Support
|
|
For issues with the video player, please contact TOTAL CME at 267-395-0001. For issues with your CE certificate, please contact Meniscus Educational Institute at 610-834-1810 |
|
|
|